

1 **Title page**

2

3 **Title**

4 Long stability of SARS-CoV-2 RNA in dry and saliva swab samples stored for  
5 diagnostics, Denmark

6

7 **Authors**

8 Alonzo Alfaro-Núñez<sup>1\*</sup>, Stephanie Crone<sup>2</sup>, Shila Mortensen<sup>1</sup>, Maiken Worsøe  
9 Rosenstjerne<sup>1</sup>, Anders Fomsgaard<sup>1</sup>, Ellinor Marving<sup>1</sup>, Sofie Holdflod Nielsen<sup>3</sup>,  
10 Michelle Grace Pinto Jørgensen<sup>3</sup>, Arie S. Cohen<sup>3</sup> and Claus Nielsen<sup>1</sup>

11

12 **Affiliations**

13

14 <sup>1</sup> Department of Virus and Microbiological Special Diagnostics, Statens Serum  
15 Institut, Artillerivej 5, 2300 Copenhagen S, Denmark

16

17 <sup>2</sup> SSI Diagnostica, Herredsvejen 2, 3400 Hillerød, Denmark

18

19 <sup>3</sup> TestCenter Danmark, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S,  
20 Denmark

21

22 \* **Correspondence:** [alonzoalfaro@gmail.com](mailto:alonzoalfaro@gmail.com), [alnz@ssi.dk](mailto:alnz@ssi.dk)

23

24 **Abstract**

25

26 During the current COVID-19 pandemic, Danish authorities demand that clinical  
27 swab samples must be analysed within 72 hours. This time constraint was adopted  
28 to guarantee a quick and efficient response. As today, analysis results are given  
29 within 20 hours average fulfilling this demand. However, it is unclear for how long  
30 and under which conditions swab specimens can be stored without clinically  
31 affecting SARS-CoV-2 RNA stability. This study demonstrates that swabs specimens  
32 can be stored at -20°C and +4°C for up to 26 days without affecting RT-qPCR  
33 results. However, early detection of asymptomatic cases is important to reduce  
34 spreading COVID-19 may be the final consequence not only in Denmark but  
35 worldwide.

36

37 **Keywords**

38

38 Viral survival, COVID-19, surveillance, clinical samples, oropharyngeal, saliva, RNA

39

39 quantification methods

40

41 **Rapid increase of SARS-CoV-2 clinical sampling**

42

43 As the number of cases of COVID-19, severe acute respiratory syndrome  
44 Coronavirus 2 (SARS-CoV-2), keep rapidly increasing during the current pandemic,  
45 there are no signs of the disease slowing down during a the second or even third  
46 wave of infection. As such, numbers of clinical samples for detection of SARS-CoV-2  
47 continue to grow worldwide (<https://www.ecdc.europa.eu/en/covid-19/data> and  
48 <https://www.cdc.gov/coronavirus/2019-ncov/index.html>). The increasing number of  
49 samples put pressure on logistics at the various test laboratories and challenges  
50 their ability to analyse samples in a timely fashion. While new, innovative and faster

51 methods for screening and diagnosing patients are constantly being developed (e.g.  
52 CRISPR-Cas based, and other isothermal amplification methods, conventional  
53 antigen-based test for viral proteins, PCR assays for detecting viral amplicons),  
54 extraction of nuclei acids, followed by either reverse transcription polymerase chain-  
55 reaction (RT-PCR) or real-time RT-PCR (RT-qPCR) approaches, remain the most  
56 commonly used due to their high sensitivity and relatively low cost (1).

57

58 Healthcare institutions, research labs and governments have made great efforts to  
59 maintain the flow of analytical diagnostics on time to provide results for the adequate  
60 detection of positive SARS-CoV-2 clinical cases worldwide.

61

62 In Denmark, there are two different test tracks available. Hospitals across the  
63 country run the health test track and are responsible for testing people with clear  
64 COVID-19 symptoms. While Test Centre Denmark (TCDK) at the Statens Serum  
65 Institut (SSI) runs the society test track (STT), which allows asymptomatic persons,  
66 or people with only mild symptoms, or even people who just wants to know their  
67 health status to be tested. One of the main premises while establishing TCDK during  
68 the early 2020 was that machines, consumables and reagents used at this facility,  
69 must not be the same as the ones used at the health track, to avoid the shortage  
70 experienced during the early stages of the pandemic across all Europe, and  
71 worldwide. Up today, TCDK runs in average more than 100,000 COVID-19 tests a  
72 day as the government recommends every person going physically to work to be  
73 tested at least once a week.

74

75 Additionally, the established procedure by SSI requires and demands that all  
76 COVID-19 clinical swabs have to be analysed within 72 hours after sample  
77 collection. In fact, over 90% of the samples are analysed and results are given within  
78 20 hours average. Any sample received and analysed after this time limit is reported  
79 as inconclusive and then discarded. The rationale for the 72-hour deadline is based  
80 on two principals. The first principal is that for a testing strategy to be effective  
81 results must be available as soon as possible. As the final results represent a  
82 moment in time, a delayed outcome may no longer signify the actual health status of  
83 a patient. Moreover, persons with even slight symptoms are expected to self-  
84 quarantine while waiting for the results and this is a substantial burden. The second  
85 principal is that when large scale testing was started, it was unknown how long  
86 SARS-CoV-2 RNA remains stable on clinical sample swabs. A stability below 72  
87 hours was considered reasonable (2). Furthermore, the laboratories for the STT are  
88 now centralized within two facilities across the country, samples are received from all  
89 over the nation and may be delayed in transport, which will subsequently cause them  
90 to be excluded from screening diagnostic if arrive outside this time threshold. This  
91 may represent a loss of potential COVID-19 positive cases carrying any of the  
92 different SARS-CoV-2 variants (3), and raises the question to how long does SARS-  
93 CoV-2 RNA remain stable in the clinical swab samples during transportation and  
94 before arrival to the respective analytical centre?

95

96 Despite the large volume of documentation generated in 2020 about the  
97 pathogenicity, infectivity and detection of SARS-CoV-2 and COVID-19, there is,  
98 however, only a handful of studies evaluating the longevity and conditions for SARS-  
99 CoV-2 RNA particle stability maintenance in clinical swabs samples for  
100 transportation in different medias (4-6). Furthermore, to our knowledge, there is no

101 available data on the stability of SARS-CoV-2 RNA during transportation and  
102 longevity in dry swabs (without any preservation buffer). Therefore, in our current  
103 study, we add to the previous findings on viral survival and detection in order to  
104 assess the stability at different environmental temperatures of SARS-CoV-2 RNA  
105 particles in swab material without the addition of a preservation media.

### 107 **Experimental design for viral quantification**

109 A total of 120 swabs (CLASSIQSwabs™ Dry Swabs, COPAN) were spiked with  
110 SARS-CoV-2 in the lab under two main conditions, 60 swabs in “Dry” by adding 5 µL  
111 of the virus directly to the tip of the swab, and 60 oropharyngeal swabs in “Saliva”  
112 solution sampled from one unique person, and then, by also adding 5 µL of SARS-  
113 CoV-2. No transport or stabilizing media was added in either of the two conditions,  
114 thus, both should be considered dry swabs. Swab samples were stored at three  
115 different temperatures (-20°C, +4°C and +20°C), and thereafter analysed in triplicate  
116 by RT-qPCR after 1, 3, 5, 8, 9, 15 and 26 days. All incubations took place in dark to  
117 overrule the potential effect of light UV radiation in the degradation of RNA  
118 molecules.

120 A well-characterized strain of SARS-CoV-2 (2019-nCoV/Munchen 1-2-2020/964,  
121 Charite/Berlin) diluted in PBS, was used to spike the swabs with a  $C_T$ -value of 29,4  
122 ( $\sim 10^3$  viral copies/ µL). Dilution series of the original standard sample ( $C_T$ -value of  
123 20;  $\sim 10^6$  viral copies/ µL) allowed the estimation of RNA viral copies/µL.

125 Samples were analysed at TCDK where 700 µL of PBS were added to the swabs,  
126 and the samples were left agitating on a shaker for 10 min (700RPM). Total nucleic  
127 acids were extracted from 200 µL of sample using a Biomek i7 (Beckman Coulter)  
128 and the RNAdvance Blood kit (Beckman Coulter) following the manufacturer  
129 guidelines and eluting in 50 µL DNase and RNase free water. RT-qPCR was  
130 performed on a CFX96 (Bio-Rad) using 5 µL elute in a total reaction volume of 25  
131 µL. The PCR reaction contains Luna Probe One-Step React Mix (New England  
132 Biolabs), 0,3% IGEPAL CA-630. The Primers & Probes targeting the E-gene region  
133 and Cycling conditions as described in Corman *et al.* 2020 (7). This standard set up  
134 for analysing all the SST swab samples keeps being updated and improved day by  
135 day.

### 137 **How long does SARS-CoV-2 survive in oropharyngeal dry swab clinical samples?**

140 The design of our study differed from previous investigations that compared swab  
141 types and specimen collection methods within a clinical setting (4,8). Despite the fact  
142 that nasopharyngeal swabs are considered to reach the highest-yield for diagnostic  
143 testing of SARS-CoV-2, oropharyngeal swabs and saliva are also broadly used (9).  
144 Studies suggest that saliva may be a suitable and high-yield diagnostic type of  
145 sample for detection of SARS-CoV-2. According to local viral replication, in addition  
146 to the potential mixing in saliva of lower and upper respiratory tract fluids that can  
147 carry virus (9,10). Our approach was laboratory based and no patients were  
148 involved. The analysis was only designed as a development study, using the current  
149 oropharyngeal national swab method, to provide insight into the stability of RNA viral  
150 particles in dry and saliva swabs and not in the disease itself. Even though  $C_T$  values

151 provide quantitative information over time, issues such as the relationship between  
152 viral load and disease severity could therefore not be assessed and were never the  
153 target of the current assay.

154

155 In overall, no significant variation was observed in the  $C_T$  values (and viral copy  
156 number/  $\mu\text{L}$ ) over time within the two main conditions (see Fig. 1), except for the  
157 saliva treatment at  $+20^\circ\text{C}$  which after 9 days experienced an increase in the mean  
158  $C_T$  values (from  $\sim 10^3$  to  $\sim 10^1$  viral copies /  $\mu\text{L}$  concentration decrease). A direct  
159 correlation of higher viral stability in lower temperatures over time for both main  
160 conditions was observed (Table 1). Moreover, there was also a slight tendency of  
161 saliva swab samples to give lower  $C_T$  values and thus, to be a more stable  
162 environment for the survival of SARS-CoV-2 RNA during the first 9 days of  
163 incubation. A study showed that SARS-CoV-2 could be detected using RT-qPCR on  
164 swabs after 21 days at room temperature (8). In another study, absolute dry swabs  
165 taken from clinical patients showed a slight reduction in utility for several respiratory  
166 viruses, supporting our results (2). Although, both conditions in our study should be  
167 essentially considered as dry swabs as no preservation buffer were added. The  
168 saliva swabs represented better the actual enzymatic environment found in real  
169 clinical swab samples, than the absolute dry swabs, in which only 5  $\mu\text{L}$  of the virus  
170 was added directly to the tip of the swab. Nevertheless, to our knowledge there is no  
171 study evaluating the direct effect of oropharyngeal enzymes in the stability of SARS-  
172 CoV-2 and thus, we cannot further conclude.

173

174 As mentioned above, temperature was observed to play a significant role in  
175 stabilizing the RNA molecules of the virus, in particular for the saliva swabs when  
176 compared to the dry swabs (Suppl. Mat. 1). Using linear regression, there was a  
177 statistically significant difference in  $C_T$  in the saliva swabs after 3 days ( $P = 0,003$ ),  
178 15 days ( $P = 0,003$ ) and 26 days ( $P = 0,03$ ) of incubation, and in dry swabs after 8  
179 days ( $P = 0,004$ ) incubation in between  $-20^\circ\text{C}$  and ambient room temperature  
180 ( $20^\circ\text{C}$ ). Moreover, a significant difference was also noticed for the saliva after 15  
181 days ( $P = 0,006$ ) when compared the  $+4^\circ\text{C}$  and  $+20^\circ\text{C}$  temperatures, and in the dry  
182 treatment after 8 days ( $P = 0,03$ ) in between the  $-20^\circ\text{C}$  and  $+4^\circ\text{C}$  incubation  
183 temperature (Table1). Finally, samples at  $-20^\circ\text{C}$  were slightly more stable than  $+4^\circ\text{C}$   
184 and samples at  $+20^\circ\text{C}$  showed increase in viral particles degradation with lower viral  
185 copies (Suppl. Mat. 2).

186

187 There are several available protocols and regulations for oropharyngeal swab  
188 samples collection and the different media available for transportation (11,12).  
189 Oropharyngeal swabs are among the most used type of clinical sample specimens  
190 collected in combination with nasopharyngeal swabs during the current pandemic  
191 (6). In Denmark, hospitals with the health track use different kinds of transport buffer  
192 containing a hydrolysing agent to the swabs right after collection. However, SSI with  
193 the STT does not add a transport buffer and swab samples are stored dry after  
194 collection until they reach TCDK for nuclei acid extraction and RT-qPCR analysis.  
195 There is evidence supporting that transporting dry swabs do not compromise RNA  
196 recovery from clinical samples (2). Our results confirm that the current method  
197 selected for the STT do not compromise and retain SARS-CoV-2 RNA up to 26 days  
198 (a highly surprising number of days) without a significant variation or reduction in  $C_T$ -  
199 values if the samples are kept cold. As such, implementing the use of dry swabs  
200 represents also an economical value by reducing the cost of additional preservation

201 buffers. Furthermore, the swabs used by TCDK were selected based on a  
202 preliminary assay that quantified the retention of viral particles by comparing different  
203 types of swab materials (Suppl. Mat. 3).

204

205 Denmark has become a worldwide reference for developing performance in  
206 detection of COVID-19 (8). Testing delays and laboratory bottlenecks have  
207 contributed to the aggravation spread of COVID-19 infections. Therefore, an  
208 important aspect to take into consideration supporting the innovative implementation  
209 of STT is the reduction of spreading COVID-19 by the early detection of  
210 asymptomatic cases.

211

212 As such, to have a good knowledge of stability survival of SARS-CoV-2 RNA in dry  
213 swabs can serve as reference guideline and important for planning during the current  
214 pandemic and future events.

215

216 This study demonstrates that swabs specimens can be stored at -20°C and +4°C for  
217 up to 26 days without clinically affecting RT-qPCR results.

218

## 219 **Ethical statement**

220 Exemption for review by the ethical committee system and informed consent was  
221 given by the Committee on Biomedical Research Ethics - Capital region in  
222 accordance with Danish law on assay development projects (see Journal-nr.: H-  
223 21000338).

## 224 **Acknowledgements**

225

226 We would like to extend our gratitude to Susanne Lopez Rasmussen and Bettina  
227 Andersen for their technical assistance.

228

## 229 **Author contributions**

230

231 Alonzo Alfaro-Núñez (AAN): conceptualization, writing original draft, analysis and  
232 validation, approved final MS

233 Stephanie Crone (SC): review and edit, statistical analysis, approved final MS

234 Sofie Holdflod Nielsen (SHN), Michelle Jørgensen (MJ): generation of data,  
235 approved final MS

236 Shila Mortensen (SM), Arie S. Cohen (ASC) and Claus Nielsen (CN):  
237 conceptualization, review and edit, approved final MS

238 Maiken Worsøe Rosenstjerne (MWR), Anders Fomsgaard (AF) and Ellinor Marving  
239 (EM): review and edit, approved final MS

240

## 241 **Competing interests**

242 The authors declare no competing interests.

243

## 244 **References**

245

- 246 1. D'Cruz RJ, Currier AW, Sampson VB. Laboratory Testing Methods for Novel  
247 Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Front Cell

- 248 Dev Biol. Frontiers; **2020**; 8.
- 249 2. Moore C, Corden S, Sinha J, Jones R. Dry cotton or flocked respiratory swabs  
250 as a simple collection technique for the molecular detection of respiratory  
251 viruses using real-time NASBA. Journal of Virological Methods. Elsevier; **2008**;  
252 153(2):84–89.
- 253 3. Spiess K, Alfaro-Núñez A, Marving E, et al. *Development of RT-PCR to detect*  
254 *the multigeographical variants in the SARS-CoV-2 spike glycoprotein gene*. In  
255 preparation.
- 256 4. Rogers AA, Baumann RE, Borillo GA, et al. Evaluation of Transport Media and  
257 Specimen Transport Conditions for the Detection of SARS-CoV-2 by Use of  
258 Real-Time Reverse Transcription-PCR. McAdam AJ, editor. J Clin Microbiol.  
259 American Society for Microbiology Journals; **2020**; 58(8):1564.
- 260 5. Ren S-Y, Wang W-B, Hao Y-G, et al. Stability and infectivity of coronaviruses  
261 in inanimate environments. WJCC. **2020**; 8(8):1391–1399.
- 262 6. Perchetti GA, Huang M-L, Peddu V, Jerome KR, Greninger AL, McAdam AJ.  
263 Stability of SARS-CoV-2 in Phosphate-Buffered Saline for Molecular Detection.  
264 McAdam AJ, editor. J Clin Microbiol. American Society for Microbiology  
265 Journals; **2020**; 58(8).
- 266 7. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus  
267 (2019-nCoV) by real-time RT-PCR. Eurosurveillance. European Centre for  
268 Disease Prevention and Control; **2020**; 25(3):2000045.
- 269 8. Skalina KA, Goldstein DY, Sulail J, et al. Extended storage of SARS-CoV-2  
270 nasopharyngeal swabs does not negatively impact results of molecular-based  
271 testing across three clinical platforms. Journal of Clinical Pathology. BMJ  
272 Publishing Group; **2020**.
- 273 9. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of  
274 Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular  
275 Detection: A Systematic Review and Meta-analysis. J Clin Microbiol. **2021**.
- 276 10. Chen L, Zhao J, Peng J, et al. Detection of SARS-CoV-2 in saliva and  
277 characterization of oral symptoms in COVID-19 patients. Cell Prolif. John  
278 Wiley & Sons, Ltd; **2020**; 53(12):1539.
- 279 11. Druce J, Garcia K, Tran T, Papadakis G, Birch C. Evaluation of Swabs,  
280 Transport Media, and Specimen Transport Conditions for Optimal Detection of  
281 Viruses by PCR. J Clin Microbiol. 5 ed. American Society for Microbiology  
282 Journals; **2012**; 50(3):1064–1065.
- 283 12. Rodino KG, Espy MJ, Buckwalter SP, et al. Evaluation of Saline, Phosphate-  
284 Buffered Saline, and Minimum Essential Medium as Potential Alternatives to  
285 Viral Transport Media for SARS-CoV-2 Testing. McAdam AJ, editor. J Clin  
286 Microbiol. American Society for Microbiology Journals; **2020**; 58(6).

288 **Table, Figure and Supplemental materials legends:**

289 **Table 1.** Statistical comparison of  $C_T$  values per conditions.  $C_T$  mean value results  
290 with the SD (standard deviation) values for the two main conditions, in "saliva"  
291 medium and in dry (no medium). Swabs were spiked with 5  $\mu$ L of SARS-CoV-2  
292 cultivated virus and quantified after 1, 3, 5, 8, 9, 15 and 26 days.  
293 Simultaneously, for each treatment, three different environmental temperature  
294 were evaluated (-20°C, 4°C and +20°C). Moreover, three replicas were  
295 quantified within each treatment in addition to a negative control. Finally, no  
296 transport or stabilizing media was added to neither of the two conditions, thus,  
297 both should be considered dry swabs.



298 **Figure 1.**  $C_T$  values variation and RNA viral copies /  $\mu$ L concentrations in dry and  
299 saliva swabs over time. RNA viral copies /  $\mu$ L mean concentrations over time  
300 are presented in panels **A** for saliva swabs and panel **B** for dry swabs.  $C_T$  value  
301 mean results for the two main categories, in panel **C** for saliva medium and  
302 panel **D** for absolutely dry. Swabs were spiked with 5 $\mu$ L of SARS-CoV-2  
303 cultivated virus and quantified after 1, 3, 5, 8, 9, 15 and 26 days. Simultaneously  
304 and for each treatment, three different environmental temperature were  
305 evaluated at -20°C, 4°C and +20°C. Three (3) replicas were quantified within  
306 each treatment in addition to a negative control. No transport or stabilizing  
307 media was added to neither of the two conditions, thus, both should be  
308 considered dry swabs.

309 **Supplemental Material 1.** Statistical analysis of  $C_T$  values.



310 **Supplemental Material 2.** Standard curve RNA viral copies /  $\mu$ L concentrations.

311 **Supplemental Material 3.** Detection of SARS-CoV-2 using three commercial swab  
312 types quantifying the swab retention performance.

Viral copies/ $\mu$ l



Ct values



<b>SARS-CoV-2 in saliva medium</b>							
<b>Mean CT (SD) on day:</b>							
	<b>1</b>	<b>3</b>	<b>5</b>	<b>8</b>	<b>9</b>	<b>15</b>	<b>26</b>
<b>-20°C</b>	31,4 (0,7)	32,3 (1,1)	30,8 (0,4)	32,2 (0,9)	31,6 (1,4)	31,8 (0,4)	31,5 (0,5)
<b>4°C</b>	30,9 (1,3)	31,1 (0,3)	30,9 (1,3)	31,0 (0,1)	31,2 (0,3)	32,0 (0,6)	32,0 (0,06)
<b>20°C</b>	30,8 (0,5)	29,5 (1,7)	31,8 (2,1)	30,7 (0,7)	31,3 (0,8)	34,6 (0,3)	33,4 (1,0)
<b>P values day:</b>							
	<b>1</b>	<b>3</b>	<b>5</b>	<b>8</b>	<b>9</b>	<b>15</b>	<b>26</b>
<b>-20°C vs. 4°C</b>	0,76	0,32	1	0,38	0,91	0,96	0,79
<b>-20°C vs. 20°C</b>	0,73	0,003	0,43	0,14	0,93	0,003	0,05
<b>4°C vs. 20°C</b>	1,00	0,11	0,49	0,92	1,00	0,006	0,21
<b>P values day 1 vs day 9</b>				<b>P values day 1 vs day 26</b>			
<b>-20°C</b>	1,00			1,00			
<b>4°C</b>	1,00			0,73			
<b>20°C</b>	1,00			0,03			

<b>SARS-CoV-2 no medium dry swab</b>							
<b>Mean CT (SD) on day:</b>							
	<b>1</b>	<b>3</b>	<b>5</b>	<b>8</b>	<b>9</b>	<b>15</b>	<b>26</b>
<b>-20°C</b>	31,8 (0,6)	31,9 (0,8)	31,8 (2,0)	31,1 (0,4)	31,8 (0,48)	31,2 (1,4)	31,9 (0,3)
<b>4°C</b>	33,3 (0,4)	32,8 (2,0)	31,6 (0,4)	33,2 (0,4)	32,7 (0,5)	31,2 (1,6)	32,1 (1,3)
<b>20°C</b>	32,4 (0,8)	33,8 (0,3)	32,7 (1,3)	34,0 (1,7)	33,1 (0,7)	32,5 (0,5)	33,2 (0,6)
<b>P values day:</b>							
	<b>1</b>	<b>3</b>	<b>5</b>	<b>8</b>	<b>9</b>	<b>15</b>	<b>26</b>
<b>-20°C vs. 4°C</b>	0,21	0,51	0,96	0,04	0,63	1,00	0,99
<b>-20°C vs. 20°C</b>	0,77	0,08	0,54	0,004	0,34	0,33	0,32
<b>4°C vs. 20°C</b>	0,55	0,51	0,38	0,67	0,85	0,32	0,41
<b>P values day 1 vs day 9</b>				<b>P values day 1 vs day 26</b>			
<b>-20°C</b>	1,00			1,00			
<b>4°C</b>	0,99			0,77			
<b>20°C</b>	0,98			0,97			